RATIONALE: Few previous studies have evaluated primary adherence (whether a new prescription is filled within 30 d) to controller medications in individuals with persistent asthma. OBJECTIVE: To compare adherence to the major controller medication regimens for asthma. METHODS: This was a retrospective cohort study of enrollees from five large health plans. We used electronic medical data on patients of all ages with asthma who had experienced an asthma-related exacerbation in the prior 12 months. We studied adherence measures including proportion of days covered and primary adherence (first prescription filled within 30 d). MEASUREMENTS AND MAIN RESULTS: Our population included 69,652 subjects who had probable persistent asthma and were prescribed inhaled corticosteroids (ICSs), leukotriene antagonists (LTRAs), or ICS/long-acting β-agonists (ICS/LABAs). The mean age was 37 years and 58% were female. We found that 14-20% of subjects who were prescribed controller medicines for the first time did not fill their prescriptions. The mean proportion of days covered was 19% for ICS, 30% for LTRA, and 25% for ICS/LABA over 12 months. Using multivariate logistic regression, subjects prescribed LTRA were less likely to be primary adherent than subjects prescribed ICS (odds ratio, 0.82; 95% confidence interval, 0.74-0.92) or ICS/LABA (odds ratio, 0.88; 95% confidence interval, 0.80-0.97). Black and Latino patients were less likely to fill the prescription compared with white patients. CONCLUSIONS: Adherence to controller medications for asthma is poor. In this insured population, primary adherence to ICSs was better than to LTRAs and ICS/LABAs. Adherence as measured by proportion of days covered was better for LTRAs and ICS/LABAs than for ICSs.
RATIONALE: Few previous studies have evaluated primary adherence (whether a new prescription is filled within 30 d) to controller medications in individuals with persistent asthma. OBJECTIVE: To compare adherence to the major controller medication regimens for asthma. METHODS: This was a retrospective cohort study of enrollees from five large health plans. We used electronic medical data on patients of all ages with asthma who had experienced an asthma-related exacerbation in the prior 12 months. We studied adherence measures including proportion of days covered and primary adherence (first prescription filled within 30 d). MEASUREMENTS AND MAIN RESULTS: Our population included 69,652 subjects who had probable persistent asthma and were prescribed inhaled corticosteroids (ICSs), leukotriene antagonists (LTRAs), or ICS/long-acting β-agonists (ICS/LABAs). The mean age was 37 years and 58% were female. We found that 14-20% of subjects who were prescribed controller medicines for the first time did not fill their prescriptions. The mean proportion of days covered was 19% for ICS, 30% for LTRA, and 25% for ICS/LABA over 12 months. Using multivariate logistic regression, subjects prescribed LTRA were less likely to be primary adherent than subjects prescribed ICS (odds ratio, 0.82; 95% confidence interval, 0.74-0.92) or ICS/LABA (odds ratio, 0.88; 95% confidence interval, 0.80-0.97). Black and Latino patients were less likely to fill the prescription compared with white patients. CONCLUSIONS: Adherence to controller medications for asthma is poor. In this insured population, primary adherence to ICSs was better than to LTRAs and ICS/LABAs. Adherence as measured by proportion of days covered was better for LTRAs and ICS/LABAs than for ICSs.
Authors: Andrea J Apter; Ray C Boston; Maureen George; A Lorraine Norfleet; Thomas Tenhave; James C Coyne; Kathleen Birck; Susan T Reisine; Andrew J Cucchiara; Harold I Feldman Journal: J Allergy Clin Immunol Date: 2003-06 Impact factor: 10.793
Authors: L Keoki Williams; Edward L Peterson; Karen Wells; Brian K Ahmedani; Rajesh Kumar; Esteban G Burchard; Vimal K Chowdhry; David Favro; David E Lanfear; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2011-10-21 Impact factor: 10.793
Authors: J F Maspero; E Dueñas-Meza; B Volovitz; C Pinacho Daza; L Kosa; F Vrijens; J A Leff Journal: Curr Med Res Opin Date: 2001 Impact factor: 2.580
Authors: Joshua S Benner; Robert J Glynn; Helen Mogun; Peter J Neumann; Milton C Weinstein; Jerry Avorn Journal: JAMA Date: 2002 Jul 24-31 Impact factor: 56.272
Authors: Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford Journal: Ann Am Thorac Soc Date: 2017-05
Authors: Jeffery M Franklin; Jocelyn R Grunwell; Alice C Bruce; Robin C Smith; Anne M Fitzpatrick Journal: Ann Allergy Asthma Immunol Date: 2017-05-04 Impact factor: 6.347
Authors: Alison A Galbraith; Vicki Fung; Lingling Li; Melissa G Butler; James D Nordin; John Hsu; David Smith; William M Vollmer; Tracy A Lieu; Stephen B Soumerai; Ann Chen Wu Journal: Health Serv Res Date: 2016-11-20 Impact factor: 3.402
Authors: Kedir N Turi; Tebeb Gebretsadik; Rees L Lee; Tina V Hartert; Amber M Evans; Cosby Stone; Nicholas M Sicignano; Ann C Wu; Carlos Iribarren; Melissa G Butler; Edward Mitchel; James Morrow; Emma K Larkin; Pingsheng Wu Journal: J Asthma Date: 2017-09-07 Impact factor: 2.515
Authors: Ann Chen Wu; Lingling Li; Vicki Fung; Elyse O Kharbanda; Emma K Larkin; Melissa G Butler; Alison Galbraith; Irina Miroshnik; Robert L Davis; Kelly Horan; Tracy A Lieu Journal: J Allergy Clin Immunol Pract Date: 2016-05-17
Authors: John Heintzman; Jorge Kaufmann; Jennifer Lucas; Shakira Suglia; Arvin Garg; Jon Puro; Sophia Giebultowicz; David Ezekiel-Herrera; Andrew Bazemore; Miguel Marino Journal: J Am Board Fam Med Date: 2020 Sep-Oct Impact factor: 2.657